Abstract: The present invention relates to a compound as shown in formula (I). The present invention also provides a composition and preparation containing the compound, and a method for using and preparing the compound.

Abstract: The present invention provides an application of a compound in the preparation of drug for treating myelofibrosis and the related symptoms/signs thereof, and a use of the compound. The compound is selected form one or more of a compound having a structure as shown in formula I, and a pharmaceutically-acceptable salt, prodrug, solvate and hydrate thereof.

Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions comprising such compounds and use thereof. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer.

Abstract: A compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, as well as a pharmaceutical composition thereof, a preparation method therefor, and a use in treating an SHP2 mediation diseases. The compounds of formula I exerts an effect by means of participating in the regulation of multiple processes such as cell proliferation, apoptosis, migration, and angiogenesis.

Abstract: The present invention relates to a novel compound, which has cancer therapeutic activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition comprising the compound.

Abstract: The present invention relates to a novel compound, which has cancer therapeutic activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition containing the compound.

Abstract: The present invention relates to a compound as represented by formula (I). The present invention also provides compositions and formulations containing such compounds, and methods for using and preparing such compounds.

Abstract: The present invention relates to a novel compound (formula I), which has cancer treatment activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition containing the compound.

Abstract: Provided are compounds of formula (I), which have KRAS mutation tumor regulating activity. Also provided are a method for providing these compounds and a pharmaceutical composition comprising the same.

Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.

Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.

Abstract: The presently disclosed and/or claimed inventive concept(s) relates generally to the use of nonionic hydrophobically modified polysaccharides in personal care and household care compositions. More specifically, but not by way of limitation, the presently disclosed and/or claimed inventive concept(s) relates to the use of hydrophobically-modified cellulose ethers, such as hydrophobically-modified hydroxyethylcellulose (HMHEC) polymers in personal care and household care compositions. These compositions show pronounced syneresis in aqueous solutions or in the presence of surfactants, including nonionic surfactants and anionic surfactants such as lauryl sulfate (LS) and lauryl ether sulfate (LES). It is also contemplated that the surfactants used in the compositions be sulfate free and/or multi-tailed.

Abstract: The presently disclosed and/or claimed inventive concept(s) relates generally to the use of nonionic hydrophobically modified polysaccharides in personal care and household care compositions. More specifically, but not by way of limitation, the presently disclosed and/or claimed inventive concept(s) relates to the use of hydrophobically-modified cellulose ethers, such as hydrophobically-modified hydroxyethylcellulose (HMHEC) polymers in personal care and household care compositions. These compositions show pronounced syneresis in aqueous solutions or in the presence of surfactants, including nonionic surfactants and anionic surfactants such as lauryl sulfate (LS) and lauryl ether sulfate (LES). It is also contemplated that the surfactants used in the compositions be sulfate free and/or multi-tailed.

Abstract: The presently disclosed and/or claimed inventive concept(s) relates generally to the use of nonionic hydrophobically modified polysaccharides in personal care and household care compositions. More specifically, but not by way of limitation, the presently disclosed and/or claimed inventive concept(s) relates to the use of hydrophobically-modified cellulose ethers, such as hydrophobically-modified hydroxyethylcellulose (HMHEC) polymers in personal care and household care compositions. These compositions show pronounced syneresis in aqueous solutions or in the presence of surfactants, including nonionic surfactants and anionic surfactants such as lauryl sulfate (LS) and lauryl ether sulfate (LES). It is also contemplated that the surfactants used in the compositions be sulfate free and/or multi-tailed.

Abstract: The present invention relates to a personal care composition additive for use on keratin substrates in order to provide long lasting benefits to the keratin substrate such as in conditioning systems, such as 2/1 shampoo's, leave-on and rinse off conditioners, for hair and skin, or for imparting greater water resistance to such personal care compositions as sunscreens or cosmetics.

Abstract: A portable device (10) for preventing movement of a door (5), the device (10) comprising: a support frame (11) having a base portion (12); and a leg (20) connected to the support frame (11); wherein the leg (20) is adjustable in height such that a distal end of the leg (20) is made to contact the ground when at least part of the base portion (12) is inserted beneath the door (5) in order to prevent movement of the door (5).

Abstract: The present invention relates to a personal care composition additive for use on keratin substrates in order to provide long lasting benefits to the keratin substrate such as in conditioning systems, such as 2/1 shampoo's, leave-on and rinse off conditioners, for hair and skin, or for imparting greater water resistance to such personal care compositions as sunscreens or cosmetics.

Abstract: A portable device (10) for preventing movement of a door (5), the device (10) comprising: a support frame (11) having a base portion (12); and a leg (20) connected to the support frame (11); wherein the leg (20) is adjustable in height such that a distal end of the leg (20) is made to contact the ground when at least part of the base portion (12) is inserted beneath the door (5) in order to prevent movement of the door (5).

Abstract: The invention provides a method for upregulating cholecystokinin (CCK) expression in mammalian pancreatic islets by administrating a CCK upregulating agent. The increased CCK expression activates islet cell proliferation triggering an increase in pancreatic ?-cell mass and plasma insulin levels. Accordingly, methods to produce a replenishable supply of islet cells and to ameliorate the symptoms associated with diabetes are also disclosed.

Abstract: The invention provides an assay for identifying agents that can prevent and treat diabetes. Specifically, the assay is a novel tool for identifying agents that can up regulate cholecystokinin (CCK) expression in pancreatic islets of mammals. The increased expression of CCK triggers an increase in pancreatic ?-cell mass and plasma insulin levels, which have been found to protect against the onset of diabetes. Also, disclosed are representative therapeutic agents identified through the assay of the invention. The methods of the invention are efficient and readily amenable to high-throughput drug screening protocols.